Beacon Therapeutics
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company develops gene therapies targeting blinding retinal diseases, including X-linked retinitis pigmentosa (laru-zova), geographic atrophy, and inherited cone-rod dystrophies.
Leadership & Board
- Current Number of Employees
- 95
- Current LinkedIn Followers
- 10,939
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $75M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $75M
- Latest Funding Round
- Series C
- Post-Money Valuation
- ―
Company Momentum Positive
Beacon Therapeutics LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Beacon Therapeutics had 95 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Beacon Therapeutics had 10,939 followers as of October 12, 2026. The number of followers increased by 91 (0.84%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 08, 2026 | Series C | $75.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Oxford Science Enterprises | Series C |
| Forbion | Series C |
| Advent Life Sciences | Series C |
| Retinal Degeneration Fund | Series C |
| Life Sciences at Goldman Sachs Alternatives | Series C |
| Syncona Limited | Series C |
Similar Companies
A snapshot of private companies similar to Beacon Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
